CURRENT STATUS OF PAN AMERICAN NETWORK FOR DRUG REGULATORY HARMONIZATION (PANDRH):

Similar documents
PAN AMERICAN NETWORK FOR DRUG REGULATORY HARMONIZATION (PANDRH)

Pan American Network on Drug Regulatory Harmonization (PANDRH)

Preventing disease Promoting and protecting health

Regulatory system strengthening

Global Development of Drugs and Co-operation among Asian Economies

New challenges on regulation of biotechnological products in peru

National Veterinary Assay Laboratory Ministry of Agriculture, Forestry and Fisheries

Patients are waiting: How regulators collectively make a difference Present challenges and opportunities - roadmap for the future

Pharmacovigilance. Interaction with the Regulatory Agency. Murilo Freitas Dias ! "#$ Salvador September 26, 2006

Regulatory system strengthening for medical products

WHO PQ dossier Module I. DCVMN Common Technical Document (CTD) Workshop Brazil, 18 to 20 June 2018 Dr. Nora Dellepiane

HTAi/ WHO Collaboration Plan Template for

PAHO HQ Library Cataloguing-in-Publication

Regulation, Norms and Standards for medical products *

Accession Preparation: Situation in Croatia

Regulation of Medical Devices in the Americas

HARMONIZATION PROCESS FOR MEDICINES REGULATION IN THE SADC REGION MANDISA HELA HELA ON ON BEHALF OF SADC SADC SECRETARIAT GABORONE, BOTSWANA

Role of Official Medicines Control Laboratories (OMCL) in assessing quality of biologicals.

Strengthening the Regulation of Medical Products through Networking, Cooperation & Harmonization

Clinical aspects during Prequalification of vaccines. Olivier Lapujade World Health Organization, EMP/RHT/PQT

Vaccine Prequalification Dossier

REGULATION OF BIOLOGICAL PRODUCTS IN PERU. Vicky Roxana Flores Valenzuela General Directorate of Medicines, Supplies and Drugs (DIGEMID)

Data Collection Tools Functions, Indicators & Sub-Indicators

Regulatory capacity building and NDRA approvals of prequalified products

fact sheet 7 Regulator Capacity for Biologics in Low-and- Middle Income Countries

Rasha Sayed Salama, MD, PhD, UAE

Update on GCC Region. 8 May Prof. Saleh Bawazir Vice President for Drug Affairs Saudi Food and Drug Authority Riyadh, Saudi Arabia

CIOMS Guide to Active Vaccine Safety Surveillance: Report of CIOMS Working Group on Vaccine Safety

Progress Report on Recommendations of 14 th International Conference of Drug Regulatory Authorities (ICDRA) from WHO South-East Asia Region (SEAR)

Access to High Cost Medicines: Examples from the Americas

Pharmaceutical Sector Governance in the Middle East and North Africa Region A Regional Review by the World Bank

Medical Devices: They Matter Too!

A WHO Perspective. International Congress on Reform and Development of the Health Care System in Kurdistan Region-Iraq. Erbil.

to protect human health throughout the life-cycle of medicinal products;

Medical Devices: how interesting they are!

Report on meetings of expert committees and study groups 1

PMDA Update: Its current situation and future direction

Fast program of the Second International Week on Regulatory Science and Good Regulatory Practices

Process for development of a revised National Regulatory Authority assessment tool harmonized across all medicines including vaccines

Review of the Member State mechanism on substandard/spurious/falsely-labelled/ falsified/counterfeit medical products

EMA and international cooperation

New Regulation in Japan and Future Direction of PMDA. Tatsuya Kondo, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA)

The Ever-increasing Complexity of Biotech Changes - A Pledge for Global Convergence

Life Cycle Management of Biotech Products An Industry Perspective. Thomas Schreitmueller

The project brief: New challenges

ROLE OF RELIANCE, RE-ENGINEERING, AND REGIONALIZATION IN THE OPTIMIZATION OF REGULATORY SYSTEMS

WHO Prequalification of in-vitro diagnostics, medicines and vaccines

Vaccines assessment overview

Kirsten L. Vadheim, Ph.D. BioCompliance Consulting, Inc. Presented at the ASBM Forum, February 25, 2014, Washington DC

European Directorate for the Quality of Medicines & HealthCare (EDQM)

2008 Pharmaceutical Package - Impact on Implementation by BfArM

WHO Pre-Qualification Programme: Facilitating Regional Approval and Patient Access to Treatments

VICH: General Principles and Global Outreach

WHO Essential Medicines and Health Products. Update at IPC Washington DC, Dec 11-12, 2012

WHO updates on Regulatory System Strengthening and Prequalification activities

Updates. APEC Life Science and Innovation Forum Regulatory Harmonization Steering Committee (APEC LSIF-RHSC) HO CHI MINH VIET NAM, August, 2017

I. The central policy framework for a national and regional strategy on sustainable consumption and production should be (see details in Annex 1):

Japanese Pharmacopoeia s Challenge to the Globalization

Draft Guidance Document Harmonized Requirements for the Licensing of Vaccines and Guidelines for the Preparation of an Application

The Emerging Role of Post-Market Evidence Generation in Decision-Making: Linkages to the Product Lifecycle Approach

SNA News Number 28 May 2009

Session 4: Ensuring Product Quality Throughout the Supply Chain

VICH: General Principles and Global Outreach. Bettye K. Walters, DVM US Food and Drug Administration

Korean and APEC Perspectives: Recent trends in the regulation of biotherapeutics

Regulatory Structure, Science and Compliance in a Medical Device Manufacturer. Disclaimer Statement

Medicines Control Council & update on SA Health Products Regulatory Authority

Action points and notes. UNFPA, UN House, Copenhagen Denmark

Workshop on Business Modeling for Sustainable Influenza Vaccine Manufacturing

Overview of global registration of vaccines

Regulatory Updates in Taiwan

Updates on NRA strengthening activities by WHO

Current Challenges of Regulation in Japan - Amendment of Pharmaceutical Affairs Act

Legislation, Transition and Implementation Medicines Control Council & SA Health Products Regulatory Authority. SAAPI Conference April 2016

Pharmacovigilance: Vigilantia initiative

EUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS

WHO NRA assessment tool: medical devices and diagnostics

Guidance Document Harmonized Requirements for the Licensing of Vaccines and Guidelines for the Preparation of an Application

Pharmacovigilance for biotherapeutics: Partnering for patient safety

Legislative and Regulatory Modernization for Therapeutic Products

RECENT TRENDS IN THE REGULATION OF BIOTECHNOLOGICAL PRODUCTS IN PERU

Research reporting and its integration into international policies on research for health in Latin America and the Caribbean (LAC)

Regulatory Challenges and Constraints when Evaluating Vaccine Clinical Trials

Ensuring Quality of Donated Medicines and Supplies during a Global Health Emergency

The Council of Europe. EDQM Milestones (1) EDQM Milestones (2) European Directorate for the Quality of

FIP STATEMENT OF POLICY Pharmacist's authority in pharmaceutical product selection: therapeutic interchange and substitution

CAREER DEVELOPMENT FOR EXPERIENCED REGULATORY PROFESSIONALS

Approved by Resolution of the Ministry of Health of the Republic of Belarus No. 55 dated April 23, 2015

Updates. APEC Life Science and Innovation Forum Regulatory Harmonization Steering Committee (APEC LSIF-RHSC) NHA TRANG VIET NAM, FEBRUARY, 2017

Vaccine Licensure: African Perspective

Regulatory Paradigms for Change: A Singapore Perspective. Dr John Lim Chief Executive Officer HEALTH SCIENCES AUTHORITY

Global Harmonization Summit Washington DC, September 18-19, 2014 Mike Ward Health Canada

WHO Prequalification Team Vector Control Products Assessment Group

International Supply Chain: How are we handling globalisation? GCP oversight

395 South Youngs Road Buffalo, New York cognigencorp.com An On-Site 2-Day Workshop in Engineering The Pharmacometric Enterprise

US FDA and International Regulatory Efforts in Cellular and Gene Therapies

GLOBAL VACCINE SAFETY INITIATIVE TERMS OF REFERENCE

OMCL Network of the Council of Europe QUALITY ASSURANCE DOCUMENT

Global Harmonization Task Force Past, Present and Future

ADVAC ALUMNI MEETING DURING SAGE

MenAfriVac clinical development

Transcription:

CURRENT STATUS OF PAN AMERICAN NETWORK FOR DRUG REGULATORY HARMONIZATION (PANDRH): OVERVIEW AND WORKING GROUP UPDATES James Fitzgerald Advisor Essential Medicines and Biologicals PAHO Washington DC

PANDRH: Network for Drug Regulatory Harmonization 1. Establishes a Forum of Drug Regulatory Agencies (DRA) to discuss and search for solution of common problems, with DRAs leading and participating in the process. 2. Strengthens the establishment of priorities in drug regulatory harmonization processes and encourage convergence of drug regulatory systems in Region. 3. Improves access to quality, safety & efficacy drugs to improve quality of pharmaceutical markets. 4. Promotes technical cooperation where more developed DRA share knowledge and experiences with less advanced DRA Good Manufacturing Practices Bioequivalence and Bioavailability Good Clinical Practices Drug Classification Counterfeit Drugs Good Laboratory Practices Working Groups Pharmacopoeia Medicinal Plants Drug Registration Pharmacovigilance Vaccines Promotion and Marketing

PANDRH OPERATING SYSTEM Regulators Andean Area CARICOM MERCOSUR SICA NAFTA INDUSTRY Conference Secretariat Steering Committee Consumers Academia Professional Associations WG WG WG WG WG WG

Objectives of the Working Group Conduct comparative studies identifying differences in legislation and practices among countries; Exchange of national and sub-regional experiences; Formulation of proposals that facilitate regional harmonization of regulations; Identify strategies for the implementation of proposals adopted by the Conference; Implement country and sub-regional follow-up; Define plans for cooperation among countries; Support NRA in the process of implementation and dissemination of scientific knowledge;

UPDATE ON SOME OF THE WORKING GROUPS

Pharmacovigilance Mission statement To develop and strengthen pharmacovigilance through activities and proposals of harmonized regulatory actions that promote the safe and rational use of drugs as a necessary component of Public policies in the Region of the Americas Members: COL,BRA,CUB,CAN,URU,FIFARMA,ALIFAR

Objectives To promote the development and dissemination of knowledge, criteria and methodologies used in Pharmacovigilance to be used in training and education activities directed to all stakeholders related to medicines; To develop, analyze and propose the use of tools to support harmonization of Pharmacovigilance in the Region; To design and promote the work in network to exchange knowledge, communicate and support decision making related to pharmacovigilance; To foster the integration of pharmacovigilance as a necessary component of public health and medicines policies and programs; To promote research and dissemination of pharmacovigilance and its impact in public health with emphasis in patient safety.

Up date The group has elaborated a series of documents: Situational analysis of pharmacovigilance in the Americas; Glossary of terms on pharmacovigilance; Program for a workshop for NRA; Document on Good Practices on Pharmacovigilance for centers;

DRUG PROMOTION Mission statement To promote and harmonize criteria for drug promotion as a contribution to the rational use, within the scope of health policies in the Americas. Members: ECU,BAR,COR,MEX,BRA,FIFARMA,ALIFAR

Objectives To provide mechanisms and criteria to identify irregularities and demonstrate the most frequently used market strategies for drug promotion; To provide information and analysis on regulation, implementation and monitoring related to drug promotion. To promote educational activities and programs related to drug promotion aimed at health professionals, potential and effective consumers. To evaluate the operation and impact of the activities of the WG.

Up date For several NRAs, promotional activities perceived as adversely impacting national strategies for promoting the rational use of medicines. The workplan proposes a comparative study of legislation in countries on publicity of pharmaceuticals for some special products;

Vaccines Mission statement Promote the harmonization of the requirements of vaccines in order to guarantee their quality, safety and efficacy, creating efficient mechanisms to contribute to vaccine availability to all countries in the region. Members: CUB,VEN,ARG,CAN,BRA

Objectives: To harmonize requirements for authorization of vaccine clinical trials, and follow up activities that should take place to monitor this harmonization process. To harmonize technical requirements for the registration (marketing authorization) of vaccines; and monitor its implementation. To promote the exchange of information and the convergence and recognition of the vaccine regulation systems among the NRAs of the region. To set up tools and organize training activities for technical staff of NR agencies in the region. To harmonize GMP requirements, specifically for vaccines, and follow up activities should take place in order monitor this harmonization process. To promote the establishment of systems for the vigilance of Adverse Events Following Immunization (AEFI) in the region. To identify other important issues on vaccines regulation that may deserve special attention, and establish an appropriate working plan to address them.

Up date Survey completed on licensing requirements for vaccines in Member States; Harmonized Guidelines (LA / Canada) developed for registration of vaccines to be presented to the PANDHR Conference, November 2008

Good Laboratory Practices Mission statement Strengthen performance of OMCL in the countries of the Region of the Americas through the implementation of Good Laboratory Practice (GLP) to guarantee the quality of analytical results and facilitate their mutual recognition of them. Members: CHI,BRA,PAN,JAM,USP

Objectives: Support the implementation of GLP in OMCL. Preparation and dissemination of educational material for the implementation of GLP guidelines; Elaboration of a program for training and continuing education; Technical support to the countries that accept the commitment to implement GLP. Promote the establishment of an OMCL network. Formalization of the EQCP. Harmonization of reporting format for results. Preparation of a proposal for the structure of the NETWORK

Up date Improving standardization of drug quality testing through the External Quality Control Program; Norms & procedures for EQCP; Training: National courses in GLP; Regional seminars on HPLC & Dissolution; Evaluation tool for Quality Control Laboratories

Drug Counterfeiting Mission Statement Promote, facilitate, and motivate implementation of proactive strategies for preventing and fighting drug counterfeiting and thus contribute to the improvement of health care in the Americas. Members: BRA,STL,ARG,CAN,COL,FIFARMA,ALIFAR

The group is working on: Up date Developing the network; Adopting standards of Good Practices through the complete chain of commercialization; Identify mechanisms of medicines traceability; Develop educational seminars; Coordinate actions with IMPACT.

PANDHR Conference November 2008, Buenos Aires, Argentina Working Groups Review / adoption of regional harmonized norms and guidelines produced by the Working Groups Update on activities of Working Groups Presentation of NRA assessment tool adapted from WHO Guidelines by 7 NRAs in LA focuses on core functions defined by the NRAs recognizing NRAs supporting regional prequalification through the Strategic Fund Presentation of revised statutes: focus on prioritization and decision making process scope of activity for Working Groups, role in capacity building strengthening participation and articulation with sub-regional blocs

PANDHR Sub-regional Blocs NAFTA MERCOSUR SICA ANDEAN COMMUNITY CARICOM

.. THANK YOU